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ABSTRACT 
Vaccinia virus (VACV) envelope protein 
D8 is one of three glycosaminoglycan adhesion 
molecules and binds to the linear polysaccharide 
chondroitin sulfate (CS). D8 is also a target for 
neutralizing antibody responses that are elicited by 
the smallpox vaccine, which has enabled the first 
eradication of a human viral pathogen and is a 
useful model for studying antibody responses. 
However, to date, VACV epitopes targeted by 
human antibodies have not been characterized at 
atomic resolution. Here, we characterized the 
binding properties of several human anti-D8 
antibodies and determined the crystal structures of 
three VACV-MAb variants, VACV-66, VACV-
138, and VACV-304, separately bound to D8. 
While all these antibodies bound D8 with high 
affinity and were moderately neutralizing in the 
presence of complement, VACV-138 and VACV-
304 also fully blocked D8 binding to CS-A, the low 
affinity ligand for D8. VACV-138 also abrogated 
D8 binding to the high-affinity ligand CS-E, but we 
observed residual CS-E binding was observed in 
the presence of VACV-304. Analysis of the 
VACV-138 and VACV-304 binding sites along the 
CS binding crevice of D8, combined with different 
efficiencies of blocking D8 adhesion to CS-A and 
CS-E allowed us to propose that D8 has a high and 
low affinity CS binding region within its central 
crevice. The crevice is amenable to protein 
engineering to further enhance both specificity and 
affinity of binding to CS-E. Finally, a wild-type D8 
tetramer specifically bound to structures within the 
developing glomeruli of the kidney, which express 
CS-E. We propose that through structure-based 
protein engineering, an improved D8 tetramer 
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could be used as a potential diagnostic tool to detect 
expression of CS-E, which is a possible biomarker 
for ovarian cancer.  
 
Smallpox is caused by infection with 
variola virus and was a major health threat until 
successful global vaccination efforts led to its 
complete eradication from the general human 
population (1).  This eradication of an infectious 
agent was achieved by immunizing with Vaccinia 
virus (VACV), a related orthopoxvirus with low 
virulence and the active ingredient in the smallpox 
vaccine (2,3). Immunization with VACV leads to 
the robust production of highly neutralizing 
antibodies targeting several VACV envelope 
proteins, including A27, A33, B5, D8, H3, L1, and 
others, which are expressed on different viral 
envelopes (3,4). A27, D8, H3 and L1 are expressed 
on the outer membrane of the intracellular mature 
virion (IMV), while A33 and B5 are found in the 
more fragile extracellular enveloped virion (EEV), 
which has an additional host cell derived envelope. 
Both the IMV and the EEV particles are infectious 
virions, with IMV being more abundant and mainly 
responsible for spread between hosts, and EEV 
being involved in cell-to-cell spread within the host 
after infection with the IMV (5). As a result, a 
potent antibody-mediated immune response against 
VACV targets both infectious virions. 
Among the targeted envelope proteins, 
A27, D8, and H3 are glycosaminoglycan (GAG) 
adhesion molecules. GAGs are linear, mostly 
sulfated polysaccharides with repeating 
disaccharide units. The precise sulfation of each 
GAG is regulated by specific sulfotransferases, 
leading to the production of different isoforms. 
GAGs are covalently attached to various core 
proteins to form the proteoglycan (PG). They are 
ubiquitously expressed on cell surfaces and in 
extracellular matrices (6). In addition to providing 
structural integrity, GAGs participate in various 
physiological processes such as cell adhesion, cell 
proliferation, migration, neurite outgrowth, 
microbial adhesion and infection, inflammation and 
angiogenesis (7-11). Many pathogens encode 
GAG-binding proteins as a major route of entry 
(12). While A27 and H3 (13-15) bind to heparan 
sulfate (HS), D8 binds to chondroitin sulfate (CS) 
(16). Chondroitin sulfate (β-GlcA-β-(1-3)GalNAc-
sulfate) is the most abundant GAG and has 4 major 
isotypes (chondroitin-4-sulfate, CS-A; chondroitin-
6-sulfate, CS-C; chondroitin-2,6-sulfate, CS-D; 
chondroitin-4,6-disulfate, CS-E) in mammals (17). 
We have determined previously the structure of 
VACV D8 protein, which revealed an N-terminally 
located carbonic anhydrase (CAH) domain 
(residues 1-235), followed by a disordered stalk 
region (residues 236-267) that is required for higher 
oligomeric assembly of the D8 hexamer in solution, 
and for embedding D8 in the virial envelope 
(18,19). We have further identified CS-E as the 
optimal ligand for D8 and identified a positively 
charged crevice as the CS binding site (19). 
Computational docking suggested that the crevice 
is capable of binding to at least an octasaccharide 
of CS-E (18).  
We also previously characterized the 
binding pattern for a panel of D8-reactive murine 
antibodies, all of which targeted the CAH domain 
rather than the stalk region, and can be grouped into 
4 different specificity groups based on cross-
blocking studies (18,20,21). One of these 
antibodies, LA5, is moderately neutralizing in the 
presence of complement and prevents D8 binding 
to CS-E, since LA5 binds above the CS-E binding 
crevice (18,19). 
 However, to date, VACV epitopes that are 
targeted by human antibodies have not been 
characterized to atomic resolution using X-ray 
crystallography, and in total only the structures of 
eight murine antibodies bound to their VACV 
antigens A27, A33, D8, and L1 have been 
determined  (19,22-25).  
 Previously, we reported isolation of a panel 
of 21 anti-D8 human monoclonal antibodies (MAb) 
and assessed their neutralizing and protective 
capabilities (26). In this study, we have 
characterized the epitopes for some of these human 
D8 antibody and determined the first crystal 
structures of human antibodies bound to D8, using 
three clones designated VACV-66, VACV-138 and 
VACV-304. Similarly to the murine antibodies, 
human antibodies bound to the CAH domain of D8 
and were moderately neutralizing in the presence of 
complement. Two antibodies, VACV-138 and 
VACV-304, also fully blocked D8 binding to CS-
A, while VACV-304 only partially blocked D8 
binding to the high affinity ligand CS-E, revealing 
a high- and low-affinity CS binding region within 
the central D8 crevice. 
 
RESULTS 
Human anti-D8 MAbs identify a novel D8 
epitope- We analyzed four human anti-D8 MAbs 
VACV-66, VACV-138, VACV-249, and VACV-
304 for their ability to block each other’s binding to 
recombinant D8 using a real-time binding assay 
(biolayer interferometry, BLI). VACV-66 was the 
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only antibody that did not compete with any other 
MAb for D8 binding, suggesting it bound a distinct 
epitope on D8 (Fig 1A). VACV-138, VACV-249, 
and VACV-304 all competed with each other for 
binding to D8, suggesting that their epitopes on D8 
were overlapping. However, a previous study 
suggested that crossblocking of VACV-249 with 
VACV-304 depends on the order of antibodies used 
in the assay, suggesting the overlap is only partial 
(26). Next, we used ELISA to analyze the ability of 
VACV-66 and VACV-304, as representatives of 
the two major human MAb groups, to block binding 
of murine anti-D8 MAbs in a previously 
characterized antibody panel (21). We included 
representative murine MAbs from specificity 
groups I, II and IV to ask whether the human MAbs 
recognized common or unique epitopes on D8 (Fig 
1B). While VACV-304 blocked binding of mouse 
CC7.1 (group II), human VACV-66 appeared to 
recognize a unique epitope on D8, notwithstanding 
that there was slight cross-blocking with the murine 
group IV antibodies HG12 and LA5 (Fig 1). LA5 
had been shown previously to block D8 binding to 
its ligand CS-E (18,19), raising the possibility that 
some human MAbs may also prevent D8 binding to 
CS-E. 
 
Human and murine anti-D8 MAbs possess 
moderate neutralizing potency- We next tested the 
ability of anti-D8 MAbs to neutralize IMV in a flow 
cytometry-based assay. While the murine control 
anti-L1 MAb M12B9 neutralized IMV in the 
absence of complement, most anti-D8 MAbs 
required the presence of complement to neutralize 
IMV, regardless of whether they were of human or 
murine origin (Fig 2). Murine MAb JF11 was the 
only anti-D8 MAb that did not neutralize, while 
neutralization mediated by MAb JE11 also was 
weak. Compared to L1, D8 appeared to be a target 
only for antibodies with a moderate level of 
neutralizing potency, likely because the GAG 
adhesion molecules A27 and H3 can compensate 
for the function of D8.  
 
Human anti-D8 MAbs bind with high 
affinity- Next, we determined the binding affinity of 
human anti-D8 MAbs for recombinant D8. While 
VACV-66, VACV-138 and VACV-249 bound D8 
with relatively low affinity (KD= 0.35 to 1.9 nM), 
VACV-304 bound with much higher affinity 
(KD=16pM, Fig 3). MAb VACV-249 had a 
comparably low association rate (kon= 2 x 105 
1/Ms), while VACV-66, VACV-138 and VACV-
304 bound similarly fast (kon= 6.5 to 7.2 x 105 
1/Ms). Surprisingly, the high affinity of VACV-304 
was a result of extremely slow dissociation, which 
was roughly 100-times slower compared to VACV-
66 (koff= 1 x 10-5 vs. 1 x 10-3 1/s). This finding 
suggested that VACV-304 formed a stable complex 
with D8 that was characterized by a long half-life 
in solution. As the kinetic measurements were 
performed with immobilized intact IgG, only the 
1:1 binding interaction between a single Fab and D8 
was measured. Increases in avidity due to antibody 
bivalency were not addressed in this experimental 
design. As a result, binding of the antibody to D8 
embedded in the virion membrane during natural 
infection is likely even higher.   
 
Human antibodies can interfere with D8 
adhesion to CS - We next asked if any of the 
antibodies could prevent binding of D8 to its host 
ligand chondroitin sulfate-E (CS-E), similarly to 
the murine antibody LA5 (18), and whether the 
ability to block CS binding correlated with their 
neutralization capacity.  MAbs were pre-bound to 
oligomeric D8, since monomeric D8 does not bind 
to CS-A. The D8-MAb complexes were assessed 
for their binding ability to CS-A and CS-E using 
GAG microarrays (Fig 4). While VACV-66 did not 
impair D8 binding to CS-A or CS-E, both VACV-
138 and VACV-304 fully abrogated D8 binding to 
CS-A. Although binding to CS-E was greatly 
reduced when vv304 bound to D8, a low level of 
binding (25% of maximum binding) was 
consistently observed. As CS-E is the high-affinity 
D8 ligand, and CS-A is only bound by oligomeric 
D8, VACV-304 likely binds at one of the 
extremities of the crevice. This has been confirmed 
by structural studies discussed below. VACV-304 
would then leave the remainder of the D8 crevice 
uncovered and available to bind CS-E. CS-A, on the 
other hand, would not be able to bind to only a 
partially accessible D8 crevice due to its lower 
binding affinity compared to CS-E. Although the 
MAbs do not show great differences in differences 
in extent of IMV neutralization (~20-50%), all of 
the MAbs that prevented CS adhesion (VACV-138, 
VACV-304 and LA5) neutralize to slightly higher 
levels compared to MAbs VACV-66, JE11, and 
JF11 that did not block CS adhesion (Figs 2 and 3 
and (18)). VACV-249 was not included in the CS 
microarray but since its binding site on D8 partially 
overlaps with that of VACV-138 and VACV-304, 
it is likely that VACV-249 also could impair D8 
binding to CS-E.  
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Structural characterization of the D8 
epitopes targeted by human MAbs- To identify and 
characterize the D8 epitopes that are targeted by the 
human MAbs, we determined the crystal structures 
of VACV-66, VACV-138 and VACV-304 bound to 
the CAH domain of D8, to resolutions of 2.23 Å, 
2.9 Å, or 2.9 Å respectively (Table 1). 
 
VACV-66-D8 complex- VACV-66 binds on 
the side of D8, away from the CS-binding crevice, 
explaining the inability of VACV-66 to interfere 
with D8 attachment to CS-E (Fig 5). The VACV-
66 binding site on D8 is rotated 90˚ compared to the 
CS-E binding crevice and is adjacent to that of the 
murine group II, III, and IV antibodies, correlating 
with a low degree of cross-blocking with 
representative antibodies from these groups (Fig 1).  
The Fab binds to a total of 21 discontinuous 
D8 residues. The heavy chain (HC) buries a total of 
1683 Å2, while the light chain (LC) buries a total of 
313 Å2 (Table S1). The HC dominates the overall 
interactions and binds to 20 D8 residues (Gln3, 
Gln4, Asn18, Arg20, Leu21, Phe56, Pro58, Tyr61, 
Lys109, His110, Asp111, Asp112, Ile115, Leu170, 
Asp179, Val181, Asp228, Thr229, Glu230, and 
Tyr232) while the LC contacts three D8 residues 
(Asn18, Ala19, and Arg20). All three HC CDRs are 
involved in the interaction, forming an intricate H-
bond network of 21 H-bonds and one salt bridge, 
while the LC forms a cation-pi interaction between 
Tyr33L and Arg20 of D8 (Fig 6 and Table S2). 
VACV-66 exhibited a relatively fast dissociation 
from D8, possibly as a result of the lack of strong 
electrostatic, or hydrophobic interactions with D8. 
VACV-66 is the only one of the three antibodies 
studied that did not engage in salt-bridges with the 
antigen (Table S2). The VACV-66 binding site on 
D8 also is rather shallow and broad, with only 
minimal participation of the LC in antigen binding.  
 
VACV-138-D8 complex- VACV-138 
blocks D8 adhesion to CS and binds directly over 
the CS binding crevice (Fig 5). VACV-138 was not 
included in the murine antibody cross-blocking 
study, but shares several contact residues with 
murine LA5, which also interferes with CS-E 
adhesion. Compared to LA5 however, the footprint 
of VACV-138 is not located centrally above the 
binding crevice but rather is shifted along the 
crevice. VACV-138 engages D8 in a slightly tilted 
manner compared to the more centrally placed 
murine LA5 (19). The VACV-138 footprint is 
delineated by Lys48 and Glu105 at one end, and 
Thr39 and Asn175 at the other end, thereby sitting 
over both sides of the crevice.  
The Fab binds to a total of 21 discontinuous 
D8 residues and the HC buries a total of 1465 Å2, 
while the LC buries a total of 435 Å2. As a result, 
the LC is slightly more involved in D8 binding 
compared to MAb VACV-66.  Nevertheless, the 
HC dominates the overall interactions and binds to 
17 D8 residues while the LC contacts five D8 
residues (Table S1). All three HC CDRs bind D8 
with a total of 15 H-bonds and three salt bridges, 
while the LC only forms one polar interaction using 
L3 (Fig 6 and Table S2). The additional 
electrostatic interactions compared to VACV-66 
are consistent with the reduced dissociation from 
D8 and an overall higher binding affinity. 
 
VACV-304-D8 complex- Similar to 
VACV-138, VACV-304 also blocks D8 adhesion 
to CS and binds over the CS binding crevice (Fig 
5). However, in contrast to VACV-138, VACV-304 
binds closer to the end of the crevice, delineated by 
Lys48 and Lys98 on one end and Asn145 and 
Glu105 on the other end. Likely due to the slightly 
altered footprint compared to VACV-138 and the 
loss of interaction with D8 residue Asn175, the CS 
binding crevice is more accessible upon VACV-
304 binding and thus residual binding to the high 
affinity ligand CS-E was observed (Fig 4). In 
addition, slight cross-blocking with LA5 was 
observed, since VACV-304 and LA5 share the D8 
contact residues Thr39, Arg44, and Asn145, which 
are the peripheral binding residues of LA5 (19).  
The Fab binds to a total of 21 discontinuous 
D8 residues, and the HC buries a total of 1010 Å2, 
while the LC buries a total of 977 Å2. The HC binds 
to 14 D8 residues while the LC contacts ten D8 
residues (Table S1). All three HC CDRs bind D8 
with a total of 8 H-bonds, while the LC forms 5 H-
bonds and 1 salt bridge using L2 and L3 (Fig 6 and 
Table S2). In contrast to VACV-66 and VACV-
138, the LC of VACV-304 is far more involved in 
D8 binding, as judged by the buried surface area 
and the number of contact residues. This finding is 
consistent with the highest observed binding 
affinity among the tested human MAbs. 
In summary, the Fab binding affinity 
correlates well with the number of electrostatic 
interactions, as well as the involvement of the LC 
in D8 binding. VACV-66, which has the lowest 
affinity, has the least involvement of the LC in 
binding and lacks salt-bridges, while VACV-304 
has the highest affinity, establishes several salt-
bridges and also the most contacts using the LC. 
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The affinity differences are driven mostly by the 
off-rate, suggesting a locking mechanism when 
both LC and HC bind to D8, leading to a reduced 
off-rate. VACV-304 has a 100-fold reduced off-rate 
compared to VACV-66. 
 
Antibody binding to D8 mutants- We 
generated a panel of ten D8 mutants in which either 
one (Gln3, Tyr85, Tyr101, Glu105, Glu106, 
Asp112, Asn1675, and Arg220) or two 
(Arg44/Arg220 and Lys48/Arg220) residues were 
replaced with alanine to assess the effect of a 
particular amino acid side chain in antibody binding 
(S1 Fig). The D8 double mutants Lys48/Arg220 
and Arg44/Arg220 had been shown previously to 
abrogate D8 binding to CS-E (18).  
 
MAb VACV-66- None of the mutations 
tested significantly affected VACV-66 binding. Of 
the ten mutants, Gln3 and Asp112 are contact 
residues but did not appear to be critical for binding. 
In the structure, Gln3 forms a H-bond with Tyr55H 
of VACV-66, but since the carboxylate of Asp179 
also contacts Tyr55H, the interaction with Gln3 
appears to be dispensable. Asp112 forms two 
potential H-bonds with Y60H but since the 
mutation has no effect, loss of these interactions is 
likely compensated for by the other contact 
residues. Several D8 mutants appear to increase 
antibody dissociation slightly, but since they are 
located outside the binding interface they likley 
have an allosteric rather than a direct effect on the 
antibody binding. 
  
MAb VACV-138- Binding of VACV-138 to 
the D8 mutants Arg44Ala/Arg220A was abrogated, 
since Arg44 is a centrally located contact residue 
that binds to Asp52H through two salt-bridges. The 
Lys48Ala/Arg220Ala mutant only showed slightly 
increased dissociation, suggesting contact of 
VACV-138 with Lys48, which lies at the periphery 
of the epitope. This finding was somewhat 
surprising, given that Lys48 engages both Thr28H 
with an H-bond and Asp31H using a salt-bridge. 
Arg220, which is present in both mutants, is not 
part of the epitope, and as such the Arg220Ala 
single-position mutant did not exhibit reduced 
binding to VACV-138. The Glu105Ala mutation 
also demonstrated no effect on binding since it is 
located at the periphery of the epitope as well (Fig 
5).  
 
Mab VACV-304- Since VACV-304 binds 
D8 slightly offset along the CS binding crevice 
compared to VACV-138, VACV-304 binding to 
the mutant Arg44Ala/Arg220Ala was not impaired, 
in contrast to the binding of VACV-138. Arg44 is 
not a contact residue for VACV-304, although 
VACV-304 and VACV-138 bind at a similar D8 
site. This finding is in contrast to that for VACV-
138, for which the binding to the two 
aforementioned mutants was reversed. Lys48 is a 
LC contact and appeared important for D8 binding, 
since it engaged both Asp50L with a salt-bridge and 
also forms extensive non-polar VdW interactions 
with Phe31L.  
 
The D8 crevice has a low- and high-affinity 
binding region for CS-E- As VACV-304 binds to 
one extremity of the CS-E binding crevice, residual 
binding to the high affinity ligands CS-E was 
observed consistently (Fig 4). At least half of the 
binding crevice was not covered upon VACV-304 
binding (Fig 7). As CS-A binding was not observed 
in the presence of VACV-304, we postulate that 
there is an affinity threshold necessary for binding, 
which is not reached by CS-A but is by CS-E, 
correlating with the finding that CS-A is a lower 
affinity ligand for D8. It should be noted that 
monomeric D8 does not bind to CS-A but only to 
CS-E (18). In addition, LA5 binds to the opposite 
extremity of the binding crevice and fully blocks 
CS-E binding. Therefore, we speculate that the 
binding crevice in D8 has a high- and low-affinity 
CS binding region. A detailed view at the D8/CS-E 
computationally docked model correlates well with 
a high-affinity CS binding region located at the C-
terminal end of the D8 crevice, which starts with 
residues Arg220 and His176 and ends in the middle 
of the crevice around Lys108 and Arg44 (S2 Fig). 
This region is covered by the antibody LA5 but is 
accessible when VACV-304 is bound. In this 
model, more polar interactions with CS-E are 
predicted in the high affinity region compared to the 
low affinity region, where only a few interactions 
are predicted. In conclusion, the low-affinity CS 
binding region is amenable to protein engineering 
to increase the specificity and affinity towards CS-
E.  Such a protein would be useful in generating a 
highly specific and high-affinity CS-E binding 
reagent for detecting changes in CS-E expression in 
various tissues, which would correlate with cancer 
progression, since CS-E has been identified as a 
potential biomarker for ovarian cancer (27).  
 
Immunofluorescence microscopy using D8 
tetramers- As monomeric D8 specifically binds to 
the glycosaminoglycan CS-E, we asked whether we 
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could use D8 in microscopy to identify CS-E 
expression in tissues and generated a D8 tetramer 
conjugated to Alexa Fluor 488 (AF488). Since the 
CS-E specific antibody GD3G7 was reported to 
bind to developing glomeruli of the kidney (27), we 
assessed the staining of D8 on kidney sections 
isolated from one week old mice. Glomeruli were 
stained in green using phalloidin, a toxin with high 
affinity for F-actin enriched in these structures and 
D8 control tetramer, which cannot bind to CS-E, in 
red (Fig 8). While D8 does indeed bind to specific 
structures in glomeruli, it only stains localized 
regions, suggesting a highly specific binding 
pattern. The D8 control tetramer showed no binding 
to the glomerulus, in contrast to wildtype D8. 
However, there was a low-grade immunoreactivity 
of this reagent to adjacent regions. This altered 
binding behavior likely is the result of the four 
introduced mutations (Lys41Ala, Arg44Ala, 
Lys48Ala, Arg220Ala) that greatly reduce the 
positive charge of D8 and may favor hydrophobic 
interactions to unknown structures outside the 
glomerulus.  
 
DISCUSSION 
Many microbes exist that express 
glycosaminoglycan (GAG) binding proteins to 
adhere to their host cells for subsequent cell entry 
and infection (28,29). These adhesion molecules 
have evolved to acquire unique binding 
specificities. Vaccinia virus (VACV) expresses 
three envelope proteins, H3, A27 and D8 that are 
glycosaminoglycan adhesion molecules. While H3 
and A27 bind to heparin and HS, D8 binds 
chondroitin sulfate (13-16). Antibodies that target 
A27, H3 and D8 can block viral adhesion to the host 
cell and protect from infection, especially if 
multiple viral envelope proteins are targeted 
simultaneously (26,30). It is difficult to correlate 
MAb binding affinity and the ability of a single anti 
D8 MAb to block viral cell adhesion with 
neutralization potency, because VACV expresses 
several antigens that can functionally compensate 
for each other. This is especially true for the three 
GAG adhesion molecules A27, H3, and D8. 
Blocking viral adhesion via one antigen is likely not 
sufficient to prevent adhesion and subsequent 
infection. However, many antibodies targeting 
several different antigens are elicited during the 
cause of viral infection, and together these 
antibodies confer protection. As a result, the 
smallpox vaccine is considered the gold standard of 
vaccines (31).    
Since GAGs are the most abundant 
heteropolysaccharides in the body and virtually 
expressed on every cell, they are ideal receptors for 
viral adhesion. They consist of long unbranched 
chains with repeating dissacharide units. Most 
GAGs, including chondroitin sulfate (CS) are 
sulfated. The precise sulfation of CS is regulated by 
specific sulfotransferases, leading to the production 
of different isoforms. All GAGs are attached to 
specific serine residues of a core-protein to form the 
proteoglycan (PG) (32). They are ubiquitously 
expressed on cell surfaces and in extracellular 
matrices. In addition to providing structural 
integrity, GAGs participates in various 
physiological processes such as cell adhesion, cell 
proliferation, migration, neurite outgrowth, 
microbial adhesion and infection, inflammation and 
angiogenesis (7-11). The upregulation of individual 
GAG-specific sulfo-transferases during cellular 
stress results in the expression of different GAG 
isoforms and can be a biomarker for cellular 
changes leading to disease or a method to monitor 
disease progression. Chondroitin sulfate (GlcAβ1-
3GalNAcβ1-4)n is the most abundant GAG and has 
3 major isotypes (chondroitin-4-sulfate, CS-A; 
chondroitin-6-sulfate, CS-C, chondroitin-4,6-O-
disulfate, CS-E) (17). The CS sulfo-transferase 
GalNAc4S-6ST, which converts CS-A into CS-E is 
upregulated in ovarian cancer and results in an 
enrichment of CS-E on the cancer cell surface, 
while CS-C and CS-E are enriched in colon 
carcinomas (33), (34). CS-E has been proposed to 
be involved in ovarian cancer tumorigenesis as it 
mediates binding of the vascular endothelial growth 
factor (VEGF) (27,33). More recently, the malaria 
protein VAR2CSA was shown to bind a form of 
CS-A that is both expressed in the placenta and 
various cancers, especially on cancer-associated 
proteoglycans including CD44 and CSPG but not 
on healthy tissues (35). These findings suggest that 
detection of defined isoforms of CS can be a useful 
diagnostic in monitoring cancer progression. 
Several anti CS-specific antibodies exist 
that target CS-A. Antibodies against different CS 
isoforms (CS-A, CS-C, and CS-E) exist but often 
their specificity toward the individual sulfation 
patterns is limited, or their epitope is rather small 
(1-2 disaccharides), leading to antibody cross-
reactivity with other similar sulfated isoforms (36-
39). The CS-E specific antibody GD3G7 also binds 
moderately to oversulfated dermatan sulfate (DS) 
from hagfish (IdoA-GalNac4S6S) and shark skin 
DS (40). Therefore, the antibody also recognizes 
IdoA, a component of dermatan sulfate and is not 
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exclusively CS specific. A new CS-E specific 
antibody has recently been reported that can 
distinguish between iduronic and glucuronic acid 
and is, similar to D8, specific for CS (and not DS) 
(39). However, as the GAGs were mostly obtained 
commercially and purified from natural source, 
heterogeneity in the CS sulfation patterns is to be 
expected, i.e. squid cartilage from Sigma is labeled 
as containing ~61% CS-E, among other CS 
structures. An additional limitation is that no 
structural information of any antibody bound to any 
CS exists so the antibody recognition of and 
interaction with a particular GAG molecular 
species is unknown. Some antibodies, such as the 
CS-E specific antibody from (36) are very specific 
but also moderately binds to the CS-E disaccharide. 
This could lead to off-target binding, e.g the CS-E 
specific antibody could stain tissues or cellular 
structures that are enriched for CS-A or CS-C but 
contain one or two CS-E disaccharides to which it 
binds, falsely suggesting that this cell expresses 
largely CS-E. In summary, the different CS binding 
antibodies have different limitations and a more 
specific CS binding reagent that recognizes longer 
stretches, such as minimally a hexamer is needed. 
This specific binding reagent would allow a more 
careful distinction of cell surface expressed CS 
isoforms and their role in disease onset or 
progression, ultimately leading to better diagnostics 
needed for biomarker discovery.  
Since D8 specifically binds to CS-E using 
a longitudinal binding crevice capable of binding at 
least 4 disaccharide units (18), we propose that the 
D8 protein is a suitable scaffold for the design of a 
highly specific CS-E binding protein as a potential 
diagnostic tool to monitor cancer progression that 
is linked to CS-E upregulation, such as ovarian 
cancer. 
 
EXPERIMENTAL PROCEDURES 
 
Human antibody generation- Human anti-
D8 MAbs VACV-66, VACV-138, VACV-249 and 
VACV-304 were generated as reported previously 
(26). Hybridoma cells secreting VACV-specific 
MAbs were generated previously (26) and grown in 
serum-free medium (Gibco). MAbs were purified 
from culture supernatants using a HiTrap 
MabSelect Sure column (GE Healthcare). 
Nucleotide sequences of variable gene segments 
were determined by Sanger sequencing from cloned 
cDNA generated by reverse transcription PCR of 
mRNA, using variable gene-specific primers, as 
reported previously (41). 
 
Murine antibody generation- Murine anti-
D8 MAbs JE11, JF11 and LA5, as well as anti-L1 
MAbs M12B9 and 39D4, were reported previously 
(19,20,23). 
 
Competition-binding ELISA- The ELISA 
assay was performed as previously reported (21). 
Briefly, recombinant D8 (residues 1-263) was 
coated on 96-well flat bottom plates, washed with 
PBS + 0.05% Tween 20 and blocked by adding 
10% fetal bovine serum. The antibody of interest 
was added to the D8 bound wells, washed off and 
the ability of a second antibody to bind 
simultaneously to D8 was assessed. For this, the 
second antibody was HRP-conjugated, and its 
binding to D8 was assessed by measuring optical 
density at 490 nm. Total cross-blocking results in 
no signal, while a distinct binding site on D8 would 
result in maximum signal of the second antibody. 
  
Antibody-mediated neutralization of virus- 
In vitro antibody neutralization was performed 
using a flow cytometry-based assay, as reported 
previously (23,26,42). Briefly, Vero E6 cells 
(ATCC, CRL-1586) were seeded in 96-well plates 
(1x105 cells/well) and allowed to adhere for 5 h. 
Cells were then infected with 1.25x104 PFU of 
purified VACV-GFP and MAbs (final MAbs 
concentration of 20 µg/mL) for 12 h at 37°C and 
5% CO2 in 50 µL in the presence (2% final 
concentration) or absence of sterile baby rabbit 
complement (CEDARLANE). 
 
D8 constructs and tetramer generation- 
The VACV (Acam2000) D8 ectodomain (residues 
1-263), as well as its carbonic anhydrase domain 
(CAH, residues 1-235), were cloned separately into 
the pET22b vector to generate hexameric (residues 
1-263) or monomeric (residues 1-235) D8 protein 
forms. For D8 tetramer generation, we added a C-
terminal 15 amino acid glycine-serine linker 
(GGGGS)3 followed by a biotin protein ligase 
(birA) tag and a hexa-histidine tag to the CAH 
construct. A CS-E binding deficient D8 quadruple 
mutant (K41A, R44A, K48A, R220A) was 
generated as a specificity control for 
immunofluorescence experiments. The resulting 
expression plasmids were transformed into 
CodonPlus BL21 cells (Agilent), and D8 
expression and purification was performed as 
reported (19). Briefly, expression was induced with 
1 mM IPTG at 37 °C for 4 h at a cell density of 0.6 
(OD600). Cells were pelleted by centrifugation (10 
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min x 4000 g), resuspended in 50 mM Tris pH8.0, 
and sheared with a microfluidizer (3 rounds at 1400 
bars, Microfluidics). Crude lysate was clarified by 
centrifugation (1 h x 50,000 g), and D8 was purified 
using ion metal affinity chromatography (IMAC) 
on 1 mL HisTrap cartridges (GE Healthcare). After 
washing the column with 20 cv of 50 mM Tris 
pH8.0, 300 mM NaCl and 20 mM imidazole, 
followed by an additional wash step with 20 cv 50 
mM imidazole containing wash buffer, D8 was 
eluted with 50 mM Tris pH 8.0, 300 mM NaCl and 
250 mM imidazole. D8 was dialyzed against 10 
mM Tris pH 8.0, 200 mM NaCl prior to size-
exclusion chromatography (SEC). For tetramer 
preparation, birA-tagged D8 was expressed and 
purified in a similar manner and biotinylated using 
the biotin protein ligase, according to 
manufacturer’s suggestions (Avidity). Free biotin 
was removed using 10 kDa MWCO filtration 
devices, and D8 was tetramerized by incubation 
with Alexa fluor conjugated streptavidin using 
molar excess of D8. (5 D8 monomers per 1 
streptavidin tetramer). D8 tetramer was purified 
from excess D8 monomer using SEC.  
 
Glycosaminoglycan microarray assay- CS 
GAGs enriched in CS-A, CS-C, CS-D, and CS-E 
(Seikagaku Corp., Tokyo, Japan), dermatan sulfate 
(DS; Sigma-Aldrich, St. Louis, MO), hyaluronic 
acid (HA; Sigma-Aldrich, St. Louis, MO), heparin 
(Hep; Neoparin, Alameda, CA), heparan sulfate 
(HS; Sigma-Aldrich, St. Louis, MO), or 
chondroitin sulfate (CS; Sigma-Aldrich, St. Louis, 
MO) were printed on poly-DL-lysine-coated glass 
surfaces, as described previously (43,44). 
Antibodies were pre-incubated at a 10-fold molar 
excess with hexameric D8 before assessing D8 
binding to CS-A and CS-E. Experiments were 
conducted as previously published (18). 
 
Real-time binding studies using biolayer 
interferometry (BLI)- Intact IgGs were loaded onto 
anti-human Fc sensor tips (at a 20 nM 
concentration) and binding to increasing 
concentrations of monomeric D8 (0.625to 40 nM) 
was measured, as previously reported (18). For 
qualitative assessment of antibody binding to 
variant D8 protein, a single antibody was loaded on 
the sensor tip and binding to wildtype D8 or seven 
variant D8 proteins was measured simultaneously 
using a saturating concentration of monomeric D8 
(5 µM). Only a complete abrogation of binding was 
considered as significant, since overall binding 
amplitudes differed between individual D8 variant 
proteins.  
 
Fab preparation- Purified IgGs for MAbs 
VACV-66, VACV-138, and VACV-304 (1 
mg/mL) were digested with 2% (w/w) activated 
papain (Sigma #P3125) for 4 h at 37 ºC in in 100 
mM Tris/HCl pH, 1 mM EDTA, 10 mM cysteine. 
The papain digestion was stopped by adding 20 mM 
Iodoacetamide (IAA). Digestion mixtures were 
dialyzed against PBS for subsequent protein A 
purification to remove undigested IgG and Fc. The 
protein A flow-through containing Fabs was 
concentrated and purified by size exclusion 
chromatography (SEC) on a Superdex S200 
GL10/300 column (GE Healthcare), using 50 mM 
Hepes, pH7.5, 150mM NaCl as running buffer.  
 
Fab-D8 complex preparation- 20% molar 
excess of monomeric D8 protein was used to 
prepare the D8:Fab complex with Fab made from 
MAbs VACV-66, VACV-138, or VACV-304. 
Complexes were prepared at low concentration 
(~0.2 mg/mL) and incubated on ice for 5 minutes, 
concentrated, and separated from unbound D8 
using SEC on a Superdex 200 100/300 GL column 
(GE). Fractions corresponding to the D8:Fab 
complexes (MW~82 kDa) were pooled and 
concentrated to ~10 mg/mL for subsequent 
crystallization. 
 
Crystallization and structure determination- 
Initially, suitable crystallization conditions were 
determined using a liquid handling robot (Phenix, 
Art Robbins ltd.) and commercially available 
screens. Quality diffracting crystals then were 
grown manually using the sitting drop vapour 
diffusion method by mixing 0.5 µL protein with 0.5 
µL precipitate; 20% PEG 3350, 200 mM sodium 
malonate pH 5.0 (D8/VACV-66 and D8/VACV-
138), or 20% PEG 400, 200 mM sodium citrate 
tribasic (D8/VACV-304). Crystals were flash-
cooled at 100 K in mother liquor containing 20% 
glycerol.  Data collection for the D8/VACV-66 
crystal included modification from a regular phi 
scan (SSRL BL11-1, Kappa =30°; 0.25 
oscillations), due to a very long axis (c=444 Å). 
Diffraction data was integrated using XDS (45). All 
diffraction data were scaled with Scala and phase 
determination by molecular replacement (MR) was 
carried out using Phaser  (46). MR template for the 
Fab VACV-66 was PDB code 4FQQ (highest 
sequence similarity), separated into variable and 
constant domains, while PDB 4E9O (D8) was used 
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as a template for D8. MR search models for VACV-
138 and VACV-304 were PDB ID 1RZ7 and PDB 
ID 3LMJ, respectively. MR solutions first were 
refined in ccp4 using rigid body refinement, 
followed by iterative rounds of model building in 
coot (47) and restrained refinement using TLS 
refinement in REFMAC5, as part of the CCPP4 
suite (48-50).  Refinement was carried out to a final 
Rcryst and Rfree of 21.8% and 25.7% (D8/VACV-66), 
25.0% and 26.9% (D8/VACV-138), or 24.7% and 
29.7% (D8/VACV-304). Data collection and 
refinement statistics are presented in Table 1. 
 
Structural analyses and presentation- The 
quality of the models was examined with the 
program Molprobity (51). Buried surface areas 
(BSA) and atomic contacts were calculated using 
PDBePISA (http://www.ebi.ac.uk/msd-
srv/prot_int/pistart.html). Figures were prepared 
using PyMOL. 
 
Accession numbers- The coordinates and 
structure factors of the D8:Fab complexes have 
been deposited in the Protein Data Bank 
(www.rcsb.org) with codes 5USH, 6B9J, and 
5USL. The genetic features of the human anti-D8 
antibodies were reported previously (26). 
 
Immunofluorescence- One week old mice 
were sacrificed by CO2 inhalation, followed by 
immediate decapitation. Kidneys were removed 
and frozen in Tissue-Tek optimum cutting 
temperature medium (Sakura Finetek). Eight 
micron cryostat sections were fixed with methanol-
free 4% formaldehyde (EMS Diasum) for 10 
minutes at room temperature. Following 2 washes 
with PBS (Gibco), slides were blocked with 5% 
normal donkey serum, 0.3% Triton X-100 in PBS 
for 1 hour and incubated with 156 ng/ml of D8 or 
control tetramer that is unable to bind to CS-E (D8 
coupled to Alexa Fluor 488 streptavidin diluted in 
1% BSA, 0.3% Triton X-100 in PBS. Following an 
overnight incubation at 4C slides were washed with 
PBS and counterstained with Alexa Fluor 647 
phalloidin (Life Technologies, 1:100) and Hoechst 
(Life Technologies, 10 µg/ml). Slides were washed 
and mounted with Prolong Gold using #1.5 
coverslips. Microscopy was performed using a 
Zeiss LSM780 confocal laser scanning microscope 
using 63x 1.4NA objective. Imaging was done 
using 405, 488 and 633 nm laser lines in a 
sequential mode to eliminate cross-talk between 
channels. Acquired Z-stacks were projected to a 
single plane and contrast was adjusted using Fiji 
(52). All images were acquired and processed in an 
identical way. Experiments were repeated 3 times 
with 2 different batches of tetramers, yielding 
similar results. 
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TABLE 1. Data collection and refinement statistics 
 
 
 
FIGURE LEGENDS 
 
FIGURE 1. Cross-Blocking of human and mouse D8 Abs reveal a novel epitope. (A) Human antibody 
cross-blocking reveals two specificity groups (columns labeled 1 and 2). (B) Overlap between mouse and 
human MAbs identify a separate epitope for VACV-66. Black cells correspond to Abs that fully block D8 
binding of each other and are thus assumed to share overlapping epitopes. Empty cells correspond to Abs 
that did not affect the D8 binding of each other. Relative strength of cross-blocking is indicated in shades 
of grey, since epitopes may overlap partially and allow simultaneous binding of both antibodies. Columns 
1-4 indicate the four different specificity groups. 
FIGURE 2. Human anti-D8 MAbs are moderately neutralizing. VACV IMV neutralization activity of 
purified human (VACV-249, VACV-304, and VACV-66) and mouse (JE11, JF11, and LA5) anti-D8 MAbs 
in the absence (black bars) or presence (red bars) of complement. Murine anti-L1 MAb (M12B9) was used 
as positive control and anti-L1 MAb 39D4 as control for a weakly neutralizing MAb.  
FIGURE 3. Real-time binding kinetics using biolayer interferometry. MAbs were immobilized on anti-
human Fc capture antibody sensors and the 1:1 binding of each Fab to monomeric D8 was measured by 
Data collection    
Antibody complex D8/VACV-66 D8/VACV-138 D8/VACV-304 
PDB ID 5USH 6B9J 5USL 
Space group P212121 C2221 P4 
Cell dimension    
       a, b, c, (Å) 55.9, 61.5, 444.4 234.3 253.8, 73.8 118.0, 118.0, 104.6 
     ɑ, β, ɣ (°) 90, 90, 90 90, 90, 90 90, 90, 90 
Resolution range (Å)  
[outer shell] 
38.8-2.23 
[2.35-2.23] 
117.1-2.9 
[3.06-2.90] 
47.8-2.9 
[3.06-2.90] 
No. of unique reflections 75,859 [10,617] 48,731 [7,089] 30,196 [4,480] 
Rpim (%) 3.5 [40.5] 7.1 [60.7] 11.2 [57.2] 
Multiplicity 6.2 [4.9] 6.2 [6.4] 3.2 [3.3] 
Average I/σI 15.7 [1.9] 8.3 [1.4] 6.5 [1.5] 
Completeness (%) 99.6 [97.5] 99.4 [99.8] 94.8 [97.1] 
    
Refinement statistics    
No. atoms 10,202 9,990 10,022 
       Protein 10,028 9,923 10,022 
       Waters 174 48 0 
Ramachandran plot (%)    
       Favored  97.0 94.7 95.2 
       Allowed  99.6 99.8 99.8 
R.m.s. deviations    
       Bonds (Å) 0.007 0.007 0.004 
       Angles (°) 1.23 1.19 0.85 
B-factors (Å2)    
       Protein  52.0 50.5 56.6 
       Waters  44.7 63.3 / 
R factor (%) 21.8 24.1 24.7 
Rfree (%) 25.7 26.8 29.7 
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dipping into increasing concentrations (colored curves) of D8. Kinetic measurements were unaffected by 
antibody avidity. All antibodies bind with high affinity. 
 
FIGURE 4. Interference of D8 binding to CS-A or CS-E by human MAbs. Hexameric D8 was incubated 
with MAbs VACV-66, VACV-138, VACV-304, or alone prior to binding to GAG microarrays. Antibody 
blocking was assessed by comparing the amount of D8 and D8-MAb complex bound to the microarray. 
Blocking experiments were performed in triplicate (+/- SEM, error bars). While VACV-66 does not block 
D8 binding to CS-A or CS-E, VACV-138 blocks binding to both. VACV-304 fully blocks binding to CS-
A while slight binding to CS-E was observed (~25% of maximum binding).  
 
FIGURE 5. Structural overview of human MAb-D8 complexes. (A) Binding of VACV-66, VACV-138, or 
VACV-304 to D8. (B) MAb footprint on D8 is colored by chain on the D8 protein otherwise shown in grey. 
Heavy chain footprint is shown in orange and light chain in green. The CS-binding site is indicated with a 
black dot (A) and a yellow line (B).  Both VACV-138 and VACV-304 bind above the CS binding crevice, 
while VACV-66 binds on the side of D8 away from the crevice. 
 
FIGURE 6. Interactions between MAbs and D8. Binding of VACV-66 (A), VACV-138 (B), or VACV-
304 (C) to D8. D8 is shown in grey and the MAb CDRs are colored as follows: L1 (green), L2 (light green), 
L3 (dark green), H1 (yellow), H2 (cyan), and H3 (orange). Potential H-bonds are indicated with blue dotted 
lines. 
 
FIGURE 7. Footprint of CS-blocking MAbs on D8. Schematic representation of MAb binding sites 
(circles) and illustration of a high- (H) and low- (L) affinity binding region for CS within the central binding 
crevice (blue rectangle) of D8.  
 
FIGURE 8. D8 tetramers specifically detect chondroitin sulfate E in tissues. Kidney tissue samples were 
flash-frozen, sectioned, fixed in 4% PFA and reacted with 156 ng/ml of either D8 or D8 control tetramers 
coupled to Alexa Fluor 488. Samples were counterstained with phalloidin to reveal dense F-actin in the 
glomerulus and with the DNA stain Hoechst. The D8 tetramer immunoreactivity was localized within the 
glomeruli. Negative control with the mutated D8 tetramer revealed absence of binding in the glomerulus 
but low-grade immunoreactivity in adjacent regions. Bar = 20 µm. 
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FIGURES 
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Figure 2 
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Figure 3 
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Figure 6 
 
 
 
 
 
 
 
 
Figure 7 
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